Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)

v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2014
Dec. 31, 2013
Concentration Risk [Line Items]    
Accounts receivable $ 5,750us-gaap_AccountsReceivableNetCurrent $ 5,750us-gaap_AccountsReceivableNetCurrent
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B [Member]    
Concentration Risk [Line Items]    
Accounts receivable $ 5,800us-gaap_AccountsReceivableNetCurrent
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember